OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).

OBM Neurobiology  publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 7.5 weeks; Submission to Acceptance: 15.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Alzheimer's Disease Research

Submission Deadline: June 30, 2020 (Open) Submit Now

About This Topic

Alzheimer's disease (AD) is a chronic neurodegenerative disease that usually starts slowly and worsens over time. The most common early symptom is difficulty in remembering recent events (short-term memory loss). It is the cause of 60–70% of cases of dementia. As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioural issues. There is no treatment that cures Alzheimer's disease or alters the disease process in the brain. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. This special issue will seek to address topics related to the causes and complications of AD, how other aspects of risk factors (e.g., lifestyle) may influence AD, and discuss interventions/solutions to prevent AD.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Review

Voice and Speech Disorders in Alzheimer’s Disease: A State-of-the-Art Review

Received: 29 June 2020;  Published: 08 September 2020;  doi: 10.21926/obm.neurobiol.2003072


Alzheimer’s disease is the most common type of dementia in the world. This manuscript attempts to review the current knowledge of neurolaryngology and speech and language therapy in Alzheimer’s disease in order to distinguish it from other neurodegenerative diseases. Only a limited number of studies carried out on Alzheimer’s disease [...]
Open Access Original Research

Dynamic Functional Connectivity Fading Analysis and Classification of Alzheimer’s Disease, Mild Cognitive Impairment and Normal Control Subjects based on Resting-State fMRI Data

Received: 29 September 2019;  Published: 01 June 2020;  doi: 10.21926/obm.neurobiol.2002059


In this paper, motivated by the fading effect in wireless communications, where severe channel fading is related to information loss during the transmission, we evaluate and analyze the fading effect in time-varying functional connectivity of AD, MCI and NC subjects based on the resting-state fMRI data, and then apply that for AD, MCI, NC [...]
Open Access Review

Insights into Brain Signal Transduction can Provide Potential Molecular Targets to Approach and Manage Alzheimer’s Disease

Received: 01 October 2019;  Published: 18 May 2020;  doi: 10.21926/obm.neurobiol.2002058


Mechanisms leading to neuronal cell death in human pathology are far from being fully delineated. Understanding the molecules involved in neuronal death and the timing of their recruitment might help to explain the natural history of degenerative processes, including the morphological abnormalities observed in Alzheimer’s disease (AD). Moreo [...]
Open Access Review

From Light to Sound: Photoacoustic and Ultrasound Imaging in Fundamental Research of Alzheimer’s Disease

Received: 24 October 2019;  Published: 30 April 2020;  doi: 10.21926/obm.neurobiol.2002056


Alzheimer’s disease (AD) causes severe cognitive dysfunction and has long been studied for the underlining physiological and pathological mechanisms. Several biomedical imaging modalities have been applied, including MRI, PET, and high-resolution optical microscopy, for research purposes. However, there is still a strong need for imaging [...]
Open Access Review

Alzheimer’s Disease: Is a Dysfunctional Mevalonate Biosynthetic Pathway the Master-Inducer of Deleterious Changes in Cell Physiology?

Received: 03 October 2019;  Published: 29 November 2019;  doi: 10.21926/obm.neurobiol.1904046


The awareness is growing that the proteins amyloid-beta (Aβ) and tau are rather a result of Alzheimer’s disease (AD) than its cause. Similarly, doubt reigns about the degree of causality of high plasma cholesterol/lipids (the fat connection) and of prenylation. An important conceptual addition to the current lines of thinking is advanced [...]
Open Access Review

Delaying Dementia: Targeted Brain Delivery Using Lipid Cubic Phases

Received: 22 August 2019;  Published: 16 September 2019;  doi: 10.21926/obm.neurobiol.1903040


Microvascular endothelial dysfunction precedes, often by decades, the cognitive decline associated with Alzheimer's disease. Hence, preservation of a healthy cerebrovascular endothelium can be an important therapeutic target. By incorporating appropriate drug(s) into biomimetic (lipid cubic phase) nanocarriers, one obtains a multitasking combi [...]